AlmirallLBTSF 85 EV-to-FCF is 47.33 as of Jun. 26, 2026, which is 155% above its 10-year median of 18.54. GuruFocus rates LBTSF with a GF Score™ of 85/100 and a GF Value™ of $16.92. The stock has 4 warning signs investors should review. Among 562 Drug Manufacturers companies, Almirall ranks worse than 74.73% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Almirall's Enterprise Value is $2,768 Mil.
Almirall's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was $58 Mil. Therefore, Almirall's EV-to-FCF for today is 47.33.
The historical rank and industry rank for Almirall's EV-to-FCF or its related term are showing as below:
LBTSF'
s EV-to-FCF Range Over the Past 10 Years
Min: -4180.51 Med: 18.54 Max: 506.25
Current: 49.13
During the past 13 years, the highest EV-to-FCF of Almirall was 506.25. The lowest was -4180.51. And the median was 18.54.
LBTSF's EV-to-FCF is ranked worse than 74.73% of 562
companies
in the Drug Manufacturers industry
Industry Median: 20.11
vs LBTSF: 49.13
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Almirall's share price for today is $15.35.
Almirall's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.281.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Almirall EV-to-FCF Related Terms
Almirall EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Almirall's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Almirall's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Almirall EV-to-FCF vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Almirall's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Almirall's EV-to-FCF falls into.
Almirall's current Enterprise Value is $2,768 Mil.
Almirall's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Almirall (LBTSF) has a EV-to-FCF of 47.33 as of Jun. 26, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Almirall and its competitors. This is 155% above median its historical median of 18.54. According to the industry distribution chart, Almirall ranks #420 out of 562 companies in the Drug Manufacturers industry, placing it in the top 74.7%.
Is Almirall's EV-to-FCF too high?
Almirall's current EV-to-FCF of 47.33 is 155% above median its 10-year median of 18.54. The Drug Manufacturers industry median EV-to-FCF is 20.11. Almirall's value of 47.33 is 135.4% above this industry median. Based on the distribution chart, Almirall ranks #420 out of 562 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Almirall has a GF Score™ of 85/100, reflecting its overall financial health beyond just this single metric.
How does Almirall's EV-to-FCF compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Almirall ranks #420 out of 562 companies for EV-to-FCF. This places Almirall in the lower half of its industry. The industry median EV-to-FCF is 20.11. Almirall's value of 47.33 is 135.4% above this benchmark. While the company's 10-year median is 18.54 vs. the industry median of 20.11, Almirall has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Drug Manufacturers company?
The median EV-to-FCF among Drug Manufacturers companies is 20.11, based on 562 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Almirall's current EV-to-FCF of 47.33 is 135.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Almirall and its competitors. For the Drug Manufacturers industry, the median EV-to-FCF is 20.11 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Almirall's current EV-to-FCF is 47.33, which is 155% above median its own 10-year median of 18.54. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Almirall stock overvalued right now?
Almirall (LBTSF) has a current EV-to-FCF of 47.33. The stock's GF Value™ is $16.92, compared to a current price of $15.35 — trading 9.3% below its estimated fair value. The current EV-to-FCF is 47.33, which is 155% above median its 10-year median of 18.54 and 135.4% above the Drug Manufacturers industry median of 20.11. Almirall's overall GF Score™ is 85/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Almirall (LBTSF), the current EV-to-FCF is 47.33 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Almirall (LBTSF) Overvalued in 2026?
Based on GuruFocus' analysis, Almirall stock appears to be undervalued.
The current stock price of $15.35 is trading 9.3% below its estimated GF Value™ of $16.92.
Key valuation signals for LBTSF:
EV-to-FCF: 47.33 (155% above median its 10-year median of 18.54)
GF Value™: $16.92 vs. price of $15.35 (9.3% below fair value)
Industry Position: 135.4% above the Drug Manufacturers median (#420 of 562)
No single metric tells the full story. See the LBTSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Almirall SA is a skin-health focused pharmaceutical company based in Barcelona and the parent company of a group engaged in the purchase, manufacture, storage, marketing, and mediation in the sale of pharmaceutical specialities and products, as well as related raw materials. The Group applies science to provide medical solutions focused on skin health diseases and partners with healthcare professionals, and its activities also include cosmetics; chemical, biotechnological and diagnostic products for human, veterinary, agrochemical and food use; instruments and accessories for the chemical, pharmaceutical and clinical industry; and research on active chemical and pharmaceutical ingredients and products.
85GF Score
Get the complete analysis for LBTSF
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LBTSF has been successfully added to your 
